SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics' Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic MalignanciesGlobeNewsWire · 16 hr ago
SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX PlatformGlobeNewsWire · Oct 8, 2026
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic MalignanciesGlobeNewsWire · Oct 7, 2026
SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy KimGlobeNewsWire · Oct 6, 2026
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)GlobeNewsWire · Sep 24, 2026
SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment WebinarGlobeNewsWire · Sep 23, 2026SRX Global Inc. develops artificial intelligence (AI)-powered solutions designed to improve decision-making, streamline operations, and strengthen risk management. The company is headquartered in Tampa, Florida.